Nicotinamide treatment robustly protects from inherited mouse glaucoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Nicotinamide adenine dinucleotide (NAD) is a key molecule in several cellular processes and is essential for healthy mitochondrial metabolism. We recently reported that mitochondrial dysfunction is among the very first changes to occur within retinal ganglion cells during initiation of glaucoma in DBA/2J mice. Furthermore, we demonstrated that an age-dependent decline of NAD contributes to mitochondrial dysfunction and vulnerability to glaucoma. The decrease in NAD renders retinal ganglion cells vulnerable to a metabolic crisis following periods of high intraocular pressure. Treating mice with the NAD precursor nicotinamide (the amide form of vitamin B3) inhibited many age- and high intraocular pressure- dependent changes with the highest tested dose decreasing the likelihood of developing glaucoma by ∼10-fold. In this communication, we present further evidence of the neuroprotective effects of nicotinamide against glaucoma in mice, including its prevention of optic nerve excavation and axon loss as assessed by histologic analysis and axon counting. We also show analyses of age- and intraocular pressure- dependent changes in transcripts of NAD producing enzymes within retinal ganglion cells and that nicotinamide treatment prevents these transcriptomic changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
NAD + in aging, metabolism, and neurodegeneration
Verdin, E. (2015) · Science · doi:10.1126/science.aac4854 · Cited by 1,319 · cited 1×
“Declining NAD is appearing as a shared mechanism in aging and neurodegeneration.(15,16) As such an important avenue in future research will be to test”
BackgroundNAD + repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., et al. (2016) · Science · doi:10.1126/science.aaf2693 · Cited by 1,255
Mouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210
Vitamin B 3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice
Williams, P. A., Harder, J. M., Foxworth, N. E., Cochran, K. E., Philip, V. M., Porciatti, V., Smithies, O., & John, S. W. M. (2017) · Science · doi:10.1126/science.aal0092 · Cited by 617
Self-citationEndogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons
Gilley, J., & Coleman, M. P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000300 · Cited by 472 · cited 1×
“NMNAT2 is emerging as a key NAD producing enzyme within axons.(25,26) New evidence shows wide variability of NMNAT2 transcript levels between human post-mortem brains.”
BackgroundOxidative stress and mitochondrial dysfunction in glaucoma
Chrysostomou, V., Rezania, F., Trounce, I. A., & Crowston, J. G. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.09.008 · Cited by 403
Axonal protection by Nmnat3 overexpression with involvement of autophagy in optic nerve degeneration
Kitaoka, Y., Munemasa, Y., Kojima, K., Hirano, A., Ueno, S., & Takagi, H. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.391 · Cited by 108 · cited 1×
“protects from axon degeneration in other models of axonopathy and glaucoma.(27) Therefore the decreased”
BackgroundMetabolic Vulnerability in the Neurodegenerative Disease Glaucoma
Inman, D. M., & Harun-Or-Rashid, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00146 · Cited by 88
Cited by
Hui, F., Tang, J., Williams, P. A., McGuinness, M. B., Hadoux, X., Casson, R. J., Coote, M., Trounce, I. A., Martin, K. R., van Wijngaarden, P., et al. (2020) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13818 · Cited by 226
Self-citationDisturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin
Harder, J. M., Guymer, C., Wood, J. P. M., Daskalaki, E., Chidlow, G., Zhang, C., Balasubramanian, R., Cardozo, B. H., Foxworth, N. E., Deering, K. E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014213117 · Cited by 127
“NAM supplementation prevents age-dependent decreases in NAD levels, transcriptional reprogramming of RGCs, mitochondrial decline, and RGC neurodegeneration (5, 7, 24, 25).”
Self-citationTreatment strategies for Leber hereditary optic neuropathy
Jurkute, N., Harvey, J., & Yu-Wai-Man, P. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000646 · Cited by 38
“There is mounting evidence that mitochondrial dysfunction plays a key role in RGC loss in glaucoma [23,24].”
Background
Metadata
- Authors
- Williams, P. A., Harder, J. M., Cardozo, B. H., Foxworth, N. E., & John, S. W. M.
- Venue
- Communicative & Integrative Biology
- Publisher
- Informa UK Limited
- Published
- 2018-01-02
- Volume
- 11
- Issue
- 1
- Pages
- e1356956
- ISSN
- 1942-0889 (ISSN-L)
- OpenAlex
- W2788331416
- Cited by
- 96
- References
- 9
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nicotinamide treatment robustly protects from inherited mouse glaucoma. https://app.cochat.ai/papers/10.1080/19420889.2017.1356956
- The paper
- Williams, P. A., Harder, J. M., Cardozo, B. H., Foxworth, N. E., & John, S. W. M. (2018). Nicotinamide treatment robustly protects from inherited mouse glaucoma. Communicative & Integrative Biology. https://doi.org/10.1080/19420889.2017.1356956
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.